Jon Coleman Sells 4,911 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jon Coleman sold 4,911 shares of DexCom stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total value of $364,052.43. Following the sale, the executive vice president directly owned 95,450 shares of the company’s stock, valued at $7,075,708.50. This represents a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jon Coleman also recently made the following trade(s):

• On Wednesday, June 3rd, Jon Coleman sold 4,912 shares of DexCom stock. The stock was sold at an average price of $73.00, for a total value of $358,576.00.

DexCom Stock Up 0.4%

DXCM opened at $72.86 on Friday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The company has a market capitalization of $28.11 billion, a P/E ratio of 31.14, a P/E/G ratio of 1.14 and a beta of 1.45. The stock has a fifty day moving average of $64.83 and a 200-day moving average of $66.98.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the firm earned $0.32 earnings per share. The company’s revenue was up 15.0% on a year-over-year basis. On average, equities analysts expect that DexCom, Inc. will post 2.57 EPS for the current year.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent analyst reports. Sanford C. Bernstein set a $77.00 price target on DexCom in a research report on Friday, May 1st. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Truist Financial restated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Finally, Raymond James Financial set a $81.00 price target on DexCom in a research report on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $82.63.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Trust Co. of Vermont grew its position in DexCom by 14.8% in the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after acquiring an additional 145 shares during the last quarter. CVA Family Office LLC grew its holdings in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the last quarter. V Square Quantitative Management LLC grew its holdings in shares of DexCom by 1.8% during the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after purchasing an additional 172 shares during the last quarter. Essex Financial Services Inc. grew its holdings in shares of DexCom by 5.7% during the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after purchasing an additional 175 shares during the last quarter. Finally, IFP Advisors Inc grew its holdings in shares of DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after purchasing an additional 178 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.